{"title":"焦虑症的药物治疗","authors":"Antonieta Also Fontanet , Natalia Echiburu Salinas , Jessica Pinto Asenjo","doi":"10.1016/j.appr.2023.100189","DOIUrl":null,"url":null,"abstract":"<div><p>The main objective of the treatment for anxiety disorders is to relieve symptoms, prevent relapse and avoid sequels. An integral therapeutic approach most be considered (psychosocial, biologic and pharmacologic). The antidepressants and anxiolytics are the mainstay pharmacological treatment. When the prescription is made, the patient must be informed of therapeutic objectives, duration and possible side effects. Age, previous treatment, tolerance, pregnancy and side effects most be considered. In Spain there is a high rate of prescription and consume of antidepressants and anxiolytics: the data of “Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)” support that the consume of antidepressants in Spain has passed from 26.5 DHD (Daily doses per 1000 habitants/Dose per day per 1000 habitants) in the year 2000 to 79.5 DHD in the year 2013; translating and increment of 200%. Regarding the anxiolytics the DHD has increased from 50.88 in 2012 to 58.09 in 2022.</p></div>","PeriodicalId":52231,"journal":{"name":"Atencion Primaria Practica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2605073023000238/pdfft?md5=6ba5152fb3bfa88e91697100d163162f&pid=1-s2.0-S2605073023000238-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Tratamiento farmacológico de los trastornos de ansiedad\",\"authors\":\"Antonieta Also Fontanet , Natalia Echiburu Salinas , Jessica Pinto Asenjo\",\"doi\":\"10.1016/j.appr.2023.100189\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The main objective of the treatment for anxiety disorders is to relieve symptoms, prevent relapse and avoid sequels. An integral therapeutic approach most be considered (psychosocial, biologic and pharmacologic). The antidepressants and anxiolytics are the mainstay pharmacological treatment. When the prescription is made, the patient must be informed of therapeutic objectives, duration and possible side effects. Age, previous treatment, tolerance, pregnancy and side effects most be considered. In Spain there is a high rate of prescription and consume of antidepressants and anxiolytics: the data of “Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)” support that the consume of antidepressants in Spain has passed from 26.5 DHD (Daily doses per 1000 habitants/Dose per day per 1000 habitants) in the year 2000 to 79.5 DHD in the year 2013; translating and increment of 200%. Regarding the anxiolytics the DHD has increased from 50.88 in 2012 to 58.09 in 2022.</p></div>\",\"PeriodicalId\":52231,\"journal\":{\"name\":\"Atencion Primaria Practica\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2605073023000238/pdfft?md5=6ba5152fb3bfa88e91697100d163162f&pid=1-s2.0-S2605073023000238-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Atencion Primaria Practica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2605073023000238\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atencion Primaria Practica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2605073023000238","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Tratamiento farmacológico de los trastornos de ansiedad
The main objective of the treatment for anxiety disorders is to relieve symptoms, prevent relapse and avoid sequels. An integral therapeutic approach most be considered (psychosocial, biologic and pharmacologic). The antidepressants and anxiolytics are the mainstay pharmacological treatment. When the prescription is made, the patient must be informed of therapeutic objectives, duration and possible side effects. Age, previous treatment, tolerance, pregnancy and side effects most be considered. In Spain there is a high rate of prescription and consume of antidepressants and anxiolytics: the data of “Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)” support that the consume of antidepressants in Spain has passed from 26.5 DHD (Daily doses per 1000 habitants/Dose per day per 1000 habitants) in the year 2000 to 79.5 DHD in the year 2013; translating and increment of 200%. Regarding the anxiolytics the DHD has increased from 50.88 in 2012 to 58.09 in 2022.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
